Sign in

CIK 0001006281 · Non-accelerated filer<br>Smaller reporting company

Protalix BioTherapeutics, Inc.

Sign in to watch
Ticker
PLX
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
650643773
Phone
201-696-9345
Business address
2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ, 07601
Former names
ORTHODONTIX INC, EMBASSY ACQUISITION CORP
  1. 4 Other disposition Director disposed of 8,556,371 shares (other)
  2. 4 Other disposition 10% owner disposed of 8,556,371 shares (other)
  3. 4 Open-market sale Director sold 4,400,000 shares at $2.47 ($10,868,000)
  4. 4 Open-market sale 10% owner sold 4,400,000 shares at $2.47 ($10,868,000)
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 4 Open-market sale Director sold 112,330 shares at an average $5.05 ($567,563)
  8. 4 Open-market sale Director sold 10,000 shares at $5.70 ($57,000)
  9. 4 Open-market sale Director sold 35,198 shares at an average $5.79 ($203,805)
  10. 4 Open-market sale Director sold 13,135 shares at an average $5.71 ($74,970)
  11. 4 Grant or award VP, Sales & Commercial Affairs acquired 20,000 shares (grant or award)
  12. 4 Grant or award Chief Operating Officer acquired 102,000 shares (grant or award)
  13. 4 Grant or award Vice President & CFO acquired 185,000 shares (grant or award)
  14. 4 Grant or award SVP, Product Development acquired 185,000 shares (grant or award)
  15. 4 Grant or award Executive VP, R&D acquired 210,000 shares (grant or award)
  16. 4 Grant or award President & CEO acquired 418,000 shares (grant or award)
  17. 4 Open-market sale Executive VP, R&D sold 300,000 shares at $7.13 ($2,139,000)
  18. 4 Insider Changes in Ownership
  19. 4 Insider Changes in Ownership
  20. 4 Insider Changes in Ownership

Page 6 of 12 · 223 filings